Vector Labs Ab02939-10.3 Anti-PCSK9 [6E2], Human IgG1, Fc Silent™, kappa (200 μg) Centrifuge Bundle Savings at Sycamore Life Sciences

Description

Product Class: Purified
Clone ID: 6E2
Heavy Chain Modification: Fc Silent™
Synonyms: NARC1; NARC-1; PC9; Proprotein convertase subtilisin/kexin type; Neural apoptosis-regulated convertase 1; Proprotein convertase 9; Subtilisin/kexin-like protease PC9; Ab6E2
Amount: 200 μg
Application Codes Clone: WB; SPR; BLI; IP
Shipping Temperature: Wet Ice
Buffer Composition: PBS with 0.02% Proclin 300.
Original Format: IgG1
Storage Temperature: Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Chimeric Use Statement: This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG1 format, for improved compatibility with existing reagents, assays and techniques.
Specificity Statement: This antibody binds a helical conformational epitope formed by the acidic amino acid stretch comprising amino acids between Q31-A53 of the human PCSK9, particularly the segment 'DYEELVLAL'. It can bind intact human PCSK9 but can not bind mouse PCSK9. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease enzyme encoded by the PCSK9 gene in humans and it plays a role in regulation of circulating cholesterol. It is associated with autosomal dominant hypercholesterolemia, a state of elevated levels of LDL (low-density lipoprotein) cholesterol. Autosomal dominant hypercholesterolemia can result in severe implications such as stroke and coronary heart disease.
Application Notes: Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates serum LDL cholesterol (LDL-C) by interacting with the LDL receptor (LDLR) and is an attractive therapeutic target for LDL-C lowering. The epitope mapping of this antibody was done using western blotting. This antibody was able to identify a 16 kDa prodomain of recombinant PCSK9 but not the 60 kDa band comprising the catalytic and C-terminal domain in western blot. Surface plasmon resonance demonstrated that Ab6E2 (IgG1) bound to PCSK9 with a KD of 10.5 ± 1.2 nM. Biolayer interferometry experiments suggested that the formation of proper α-helix is required for the binding interaction of this antibody. This antibody was also used for immunoprecipitation of secreted native PCSK9 from HepG2, IM-95m and H2073 cell l ins and of recombinant PCSK9 (PMID: 30653992).

Product Class:	Purified
Clone ID:	6E2
Heavy Chain Modification:	Fc Silent™
Synonyms:	NARC1; NARC-1; PC9; Proprotein convertase subtilisin/kexin type; Neural apoptosis-regulated convertase 1; Proprotein convertase 9; Subtilisin/kexin-like protease PC9; Ab6E2
Amount:	200 μg
Application Codes Clone:	WB; SPR; BLI; IP
Shipping Temperature:	Wet Ice
Buffer Composition:	PBS with 0.02% Proclin 300.
Original Format:	IgG1
Storage Temperature:	Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Chimeric Use Statement:	This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG1 format, for improved compatibility with existing reagents, assays and techniques.
Specificity Statement:	This antibody binds a helical conformational epitope formed by the acidic amino acid stretch comprising amino acids between Q31-A53 of the human PCSK9, particularly the segment 'DYEELVLAL'. It can bind intact human PCSK9 but can not bind mouse PCSK9. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease enzyme encoded by the PCSK9 gene in humans and it plays a role in regulation of circulating cholesterol. It is associated with autosomal dominant hypercholesterolemia, a state of elevated levels of LDL (low-density lipoprotein) cholesterol. Autosomal dominant hypercholesterolemia can result in severe implications such as stroke and coronary heart disease.
Application Notes:	Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates serum LDL cholesterol (LDL-C) by interacting with the LDL receptor (LDLR) and is an attractive therapeutic target for LDL-C lowering. The epitope mapping of this antibody was done using western blotting. This antibody was able to identify a 16 kDa prodomain of recombinant PCSK9 but not the 60 kDa band comprising the catalytic and C-terminal domain in western blot. Surface plasmon resonance demonstrated that Ab6E2 (IgG1) bound to PCSK9 with a KD of 10.5 ± 1.2 nM. Biolayer interferometry experiments suggested that the formation of proper α-helix is required for the binding interaction of this antibody. This antibody was also used for immunoprecipitation of secreted native PCSK9 from HepG2, IM-95m and H2073 cell l ins and of recombinant PCSK9 (PMID: 30653992).

Specifications

More Information
Brand	Vector Labs
UNSPSC	12161500

Reviews